Related Experiment Video

Updated: May 6, 2026

Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion
10:42

Subculture and Cryopreservation of Esophageal Adenocarcinoma Organoids: Pros and Cons for Single Cell Digestion

Published on: July 6, 2022

3.4K

Targeted therapy for advanced esophagogastric adenocarcinoma

S Kordes1, A Cats2, S L Meijer3

  • 1Department of Medical Oncology, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands.

Critical Reviews in Oncology/Hematology
|November 5, 2013
PubMed
Abstract

Insights

Targeted therapy shows promise for advanced esophagogastric adenocarcinoma (EGC). HER2-targeted agents improve survival in HER2-positive patients, while other targeted therapies are under investigation for improved patient selection.

Area of Science:

  • Oncology
  • Gastroenterology
  • Molecular Biology

Background:

  • Esophagogastric adenocarcinoma (EGC) is a molecularly diverse cancer.
  • Targeted therapy offers a potential treatment strategy for EGC.

Purpose of the Study:

  • To review phase III studies of targeted therapies in advanced EGC.
  • To discuss biologic agents targeting EGFR, HER2, VEGFR, mTOR, and c-MET pathways.

Main Methods:

  • Review of phase III clinical trials in advanced EGC.
  • Analysis of targeted agents including EGFR, HER2, VEGFR, mTOR, and c-MET inhibitors.

Main Results:

  • HER2 inhibition with trastuzumab significantly benefits HER2-positive EGC patients.
  • Bevacizumab did not improve survival in unselected EGC patients.
  • Early trials of EGFR, VEGFR, and mTOR inhibitors showed disappointing results in unselected cohorts, but ongoing studies in biomarker-selected groups are promising.

Conclusions:

  • Targeted therapy is an emerging treatment for EGC.
  • Further understanding of EGC biology is crucial for patient selection and developing new therapies.
  • Improved strategies may enhance outcomes for metastatic EGC patients.
Keywords:
EGFREsophageal cancerGastric cancerHER2Targeted therapyVEGFRc-METmTOR

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

6.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.5K
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
1.8K
Barrett Esophagus-I: Introduction01:21

Barrett Esophagus-I: Introduction

Barrett's esophagus is a medical condition where the esophageal mucosa is significantly damaged by stomach acid or other digestive fluids, often due to long-term exposure associated with gastroesophageal reflux disease (GERD). In GERD, a weakened or abnormally relaxed lower esophageal sphincter allows stomach acid to flow persistently into the esophagus.
This constant acid exposure transforms the esophagus's pink mucosal lining (stratified squamous epithelium) into a type of lining more...
1.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
1.1K